JP7785209B2 - Ａｘｌの阻害剤としての化合物 - Google Patents

Ａｘｌの阻害剤としての化合物

Info

Publication number
JP7785209B2
JP7785209B2 JP2024574683A JP2024574683A JP7785209B2 JP 7785209 B2 JP7785209 B2 JP 7785209B2 JP 2024574683 A JP2024574683 A JP 2024574683A JP 2024574683 A JP2024574683 A JP 2024574683A JP 7785209 B2 JP7785209 B2 JP 7785209B2
Authority
JP
Japan
Prior art keywords
compound
alkyl
formula
mmol
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024574683A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025525364A5 (https=
JP2025525364A (ja
Inventor
ウォーリー ベアッティ，ジョエル
ニコル フォーリー，コリン
ガル，バリント
ラマニ，マンジュナス
レディ レレティ，マンモハン
ハーディング マイルズ，ディロン
パラドゥグゥ，スリニバス
パトリック パワーズ，ジェイ
ク，シウェイ
Original Assignee
アーカス バイオサイエンシーズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アーカス バイオサイエンシーズ，インコーポレーテッド filed Critical アーカス バイオサイエンシーズ，インコーポレーテッド
Publication of JP2025525364A publication Critical patent/JP2025525364A/ja
Publication of JP2025525364A5 publication Critical patent/JP2025525364A5/ja
Priority to JP2025216661A priority Critical patent/JP2026041858A/ja
Application granted granted Critical
Publication of JP7785209B2 publication Critical patent/JP7785209B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024574683A 2022-06-28 2023-06-27 Ａｘｌの阻害剤としての化合物 Active JP7785209B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025216661A JP2026041858A (ja) 2022-06-28 2025-12-02 Ａｘｌの阻害剤としての化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263356421P 2022-06-28 2022-06-28
US63/356,421 2022-06-28
PCT/US2023/069124 WO2024006726A2 (en) 2022-06-28 2023-06-27 Compounds as inhibitors of axl

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025216661A Division JP2026041858A (ja) 2022-06-28 2025-12-02 Ａｘｌの阻害剤としての化合物

Publications (3)

Publication Number Publication Date
JP2025525364A JP2025525364A (ja) 2025-08-05
JP2025525364A5 JP2025525364A5 (https=) 2025-10-02
JP7785209B2 true JP7785209B2 (ja) 2025-12-12

Family

ID=89324379

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024574683A Active JP7785209B2 (ja) 2022-06-28 2023-06-27 Ａｘｌの阻害剤としての化合物
JP2025216661A Pending JP2026041858A (ja) 2022-06-28 2025-12-02 Ａｘｌの阻害剤としての化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025216661A Pending JP2026041858A (ja) 2022-06-28 2025-12-02 Ａｘｌの阻害剤としての化合物

Country Status (13)

Country Link
US (2) US20230416277A1 (https=)
EP (1) EP4547246A2 (https=)
JP (2) JP7785209B2 (https=)
KR (1) KR20250027650A (https=)
CN (1) CN119365453A (https=)
AR (1) AR129722A1 (https=)
AU (1) AU2023298047A1 (https=)
CA (1) CA3260468A1 (https=)
CL (1) CL2024004060A1 (https=)
IL (1) IL317736A (https=)
MX (1) MX2024015648A (https=)
TW (1) TW202400603A (https=)
WO (1) WO2024006726A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR129722A1 (es) 2022-06-28 2024-09-18 Arcus Biosciences Inc Compuestos inhibidores de axl
WO2024233360A1 (en) 2023-05-05 2024-11-14 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
EP4720055A1 (en) 2023-05-25 2026-04-08 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
US20260116868A1 (en) 2023-10-06 2026-04-30 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
TW202523302A (zh) 2023-11-02 2025-06-16 美商阿克思生物科學有限公司 噻唑化合物及其使用方法
WO2025137370A1 (en) * 2023-12-20 2025-06-26 Arcus Biosciences, Inc. Salt forms of an axl inhibitor
WO2025250276A1 (en) * 2024-05-28 2025-12-04 Taiho Pharmaceutical Co., Ltd. Methods for treatment of non-small cell lung cancers
WO2026006759A1 (en) 2024-06-28 2026-01-02 Arcus Biosciences, Inc. Pharmaceutical compositions, dosage forms, and methods of making and using same

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008523085A (ja) 2004-12-08 2008-07-03 スミスクライン・ビーチャム・コーポレイション １ｈ−ピロロ［２，３−ｂ］ピリジン
WO2015089327A1 (en) 2013-12-11 2015-06-18 Biogen Idec Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2019238067A1 (en) 2018-06-13 2019-12-19 Beigene, Ltd. Pyrrolo [2, 3-b] pyridines or pyrrolo [2, 3-b] pyrazines as hpk1 inhibitor and the use thereof
WO2020103896A1 (en) 2018-11-22 2020-05-28 Beigene, Ltd. Pyrrolo[2,3-b]pyridines as hpk1 inhibitor and uses thereof
WO2021013083A1 (en) 2019-07-17 2021-01-28 Beigene, Ltd. Tricyclic compounds as hpk1 inhibitor and the use thereof
WO2021087112A1 (en) 2019-10-30 2021-05-06 Biogen Ma Inc. Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase
JP2021535133A (ja) 2018-08-28 2021-12-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung ブルトン型チロシンキナーゼ（ｂｔｋ）の可逆的阻害剤としての縮合イミダゾピリジン
JP2024521706A (ja) 2021-05-21 2024-06-04 アーカス バイオサイエンシーズ，インコーポレーテッド Ａｘｌ化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
PT1906965E (pt) * 2005-06-22 2015-09-03 Chemocentryx Inc Compostos de azaindazol e métodos de utilização
CA2710046C (en) 2006-12-29 2016-02-09 Rigel Pharmaceuticals, Inc. N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors
EP2078010B1 (en) 2006-12-29 2014-01-29 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
JP2010514810A (ja) 2006-12-29 2010-05-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌインヒビターとして有用な置換トリアゾール
ES2537480T3 (es) 2008-07-09 2015-06-08 Rigel Pharmaceuticals, Inc. Triazoles sustituidos con heteroarilo policíclicos útiles como inhibidores de Axl
PL2387395T3 (pl) 2009-01-16 2015-03-31 Rigel Pharmaceuticals Inc Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowym
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
TWI848141B (zh) 2019-07-04 2024-07-11 英屬開曼群島商百濟神州有限公司 及其用途
WO2021239133A1 (zh) 2020-05-29 2021-12-02 南京正大天晴制药有限公司 作为axl抑制剂的嘧啶类化合物
WO2022184152A1 (zh) 2021-03-03 2022-09-09 劲方医药科技(上海)有限公司 稠环取代的六元杂环化合物及其制法和用途
WO2022246179A1 (en) 2021-05-21 2022-11-24 Arcus Biosciences, Inc. Axl inhibitor compounds
CN115504967A (zh) 2021-06-23 2022-12-23 南京正大天晴制药有限公司 作为axl抑制剂的1,2,4-三唑化合物
AR129722A1 (es) 2022-06-28 2024-09-18 Arcus Biosciences Inc Compuestos inhibidores de axl

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008523085A (ja) 2004-12-08 2008-07-03 スミスクライン・ビーチャム・コーポレイション １ｈ−ピロロ［２，３−ｂ］ピリジン
WO2015089327A1 (en) 2013-12-11 2015-06-18 Biogen Idec Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2019238067A1 (en) 2018-06-13 2019-12-19 Beigene, Ltd. Pyrrolo [2, 3-b] pyridines or pyrrolo [2, 3-b] pyrazines as hpk1 inhibitor and the use thereof
JP2021535133A (ja) 2018-08-28 2021-12-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung ブルトン型チロシンキナーゼ（ｂｔｋ）の可逆的阻害剤としての縮合イミダゾピリジン
WO2020103896A1 (en) 2018-11-22 2020-05-28 Beigene, Ltd. Pyrrolo[2,3-b]pyridines as hpk1 inhibitor and uses thereof
WO2021013083A1 (en) 2019-07-17 2021-01-28 Beigene, Ltd. Tricyclic compounds as hpk1 inhibitor and the use thereof
WO2021087112A1 (en) 2019-10-30 2021-05-06 Biogen Ma Inc. Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase
JP2024521706A (ja) 2021-05-21 2024-06-04 アーカス バイオサイエンシーズ，インコーポレーテッド Ａｘｌ化合物

Also Published As

Publication number Publication date
US20230416277A1 (en) 2023-12-28
WO2024006726A3 (en) 2024-04-25
AR129722A1 (es) 2024-09-18
KR20250027650A (ko) 2025-02-27
WO2024006726A2 (en) 2024-01-04
JP2026041858A (ja) 2026-03-10
CL2024004060A1 (es) 2025-05-16
US12195482B1 (en) 2025-01-14
TW202400603A (zh) 2024-01-01
CA3260468A1 (en) 2024-01-04
MX2024015648A (es) 2025-02-10
EP4547246A2 (en) 2025-05-07
AU2023298047A1 (en) 2025-01-09
JP2025525364A (ja) 2025-08-05
IL317736A (en) 2025-02-01
US20240425526A1 (en) 2024-12-26
CN119365453A (zh) 2025-01-24

Similar Documents

Publication Publication Date Title
JP7785209B2 (ja) Ａｘｌの阻害剤としての化合物
CN114901660B (zh) 可作为t细胞活化剂的经取代双环化合物
EP4341261A1 (en) Axl compounds
WO2013138210A1 (en) Substituted cyclic compounds and methods of use
WO2023091726A1 (en) Inhibitors of cyclin‑dependent kinase 12 (cdk12)
KR20180021702A (ko) TBK/IKKε 억제제 화합물 및 이의 용도
WO2014193647A2 (en) Alkenyl compounds and methods of use
US20260028336A1 (en) Cbl-b inhibitors and methods of use thereof
JP2024511841A (ja) 置換された１－アリール－１’－ヘテロアリール化合物、置換された１，１’－ビヘテロアリール化合物、及びこれらを使用する方法
WO2014089280A1 (en) Alkynyl compounds and methods of use
CN104119331B (zh) 烯基化合物及其使用方法和用途
WO2025076299A1 (en) Cbl-b inhibitors and methods of use thereof
HK40116573A (zh) 作为axl抑制剂的化合物
EP4602041A1 (en) Hpk1 inhibitors and methods of use thereof
EP4705292A1 (en) Cbl-b inhibitors and methods of use thereof
US20240124490A1 (en) Inhibitors of hpk1 and methods of use thereof
US20250011318A1 (en) Cbl-b inhibitors and methods of use thereof
CN117412959A (zh) 经取代的1-芳基-1'-杂芳基化合物、经取代的1,1'-联杂芳基化合物和其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250924

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250924

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251202

R150 Certificate of patent or registration of utility model

Ref document number: 7785209

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150